论文部分内容阅读
近年来,功能性脑显像放射性药物的发展迅速,现已能用~(12?)I-碘代苯异丙胺或~(99m)Tc-HMPAO测量人体局部脑血流,另一些脂溶性的~(99m)Tc络合物目前正进行临床试验;用于测定脑神经系统受体的新型~(123)I标记药物已经开发出来,这些药物与SPECT结合,为评价与受体浓度变化有关的脑功能提供了有用的手段.此文前半部分阐述的脑灌注显像剂现状和展望,其基本内容在《Semin Nucl Med》(1990,20(2):150～158)上已作了详细的报道,本刊也曾于1990年第6期刊出该译文,故在此作了删节.
In recent years, the development of functional brain imaging radiopharmaceuticals has been rapidly developed. It is now possible to measure regional cerebral blood flow with ~ (12?) I-iodoamphetamine or ~ (99m) Tc-HMPAO. Other liposoluble ~ (99m) Tc complexes are currently undergoing clinical trials; a new class of ~ (123) I-labeled drugs have been developed for the determination of receptors on the cranial nervous system. These drugs, in combination with SPECT, are used to assess changes in receptor concentration Brain function provides a useful means.First part of the paper described in the brain perfusion imaging agent status and outlook, the basic content of “Semin Nucl Med” (1990,20 (2): 150 ~ 158) has been detailed Reported that we published the translation in the sixth issue of 1990, so we made an abridgement here.